Literature DB >> 8635124

Sequential treatment of recurrent mesenteric desmoid tumor.

T Bauernhofer1, H Stöger, M Schmid, M Smola, B Gürtl-Lackner, G Höfler, G Ranner, E Reisinger, H Samonigg.   

Abstract

BACKGROUND: The optimal management of inoperable desmoid tumors is still unclear. We report a 26 year-old female patient with familial adenomatous polyposis suffering from a recurrent inoperable intraabdominal desmoid tumor and its sequential treatment.
METHODS: Treatment strategies included low-dose tamoxifen (30 mg orally per day), high-dose tamoxifen (90 mg orally per day), and a subsequent combination of goserelin acetate (3.6 mg subcutaneously once every four weeks) plus low-dose tamoxifen, medroxyprogesterone acetate (1000 mg orally per day) and interferon gamma (3 Mio IU subcutaneously 3 times a week).
RESULTS: The combination of goserelin acetate and low-dose tamoxifen resulted in a decrease in tumour size and a complete relief of symptoms for 17 months. Thereafter the tumor progressed and again growth was stopped with interferon gamma therapy for another 6 months. All other treatment modalities had no effect.
CONCLUSIONS: This study demonstrates long-term regression of a desmoid tumor with combined endocrine therapy using goserelin acetate plus tamoxifen. Tumor progression after 17 months was again stopped by a combination of interferon-gamma and goserelin acetate.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8635124

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  11 in total

Review 1.  Intra-abdominal fibromatosis of the jejunum and mesentery.

Authors:  S A Pai; S S Zaveri
Journal:  J Clin Pathol       Date:  2004-10       Impact factor: 3.411

2.  Long-term outcome of sporadic and FAP-associated desmoid tumors treated with high-dose selective estrogen receptor modulators and sulindac: a single-center long-term observational study in 134 patients.

Authors:  Daniel Robert Quast; Ralph Schneider; Emanuel Burdzik; Steffen Hoppe; Gabriela Möslein
Journal:  Fam Cancer       Date:  2016-01       Impact factor: 2.375

3.  Extra-abdominal fibromatosis (desmoid tumor) arising in the infratemporal fossa: a case report.

Authors:  M Corsten; P Donald; J Boggan; A Gadre; R Gandour-Edwards; W Nemzek
Journal:  Skull Base Surg       Date:  1998

4.  Safety and efficacy of high-dose tamoxifen and sulindac for desmoid tumor in children: results of a Children's Oncology Group (COG) phase II study.

Authors:  Stephen X Skapek; James R Anderson; D Ashley Hill; David Henry; Sheri L Spunt; William Meyer; Simon Kao; Fredric A Hoffer; Holcombe E Grier; Douglas S Hawkins; R Beverly Raney
Journal:  Pediatr Blood Cancer       Date:  2012-12-31       Impact factor: 3.167

Review 5.  Imatinib in the treatment of solid tumours.

Authors:  Florence Duffaud; Axel Le Cesne
Journal:  Target Oncol       Date:  2009-01-27       Impact factor: 4.493

Review 6.  Control of aggressive fibromatosis by treatment with imatinib mesylate. A case report and review of the literature.

Authors:  Gabriel Wcislo; Katarzyna Szarlej-Wcislo; Cezary Szczylik
Journal:  J Cancer Res Clin Oncol       Date:  2007-04-24       Impact factor: 4.322

7.  Current trends in the management of extra-abdominal desmoid tumours.

Authors:  Panayiotis J Papagelopoulos; Andreas F Mavrogenis; Evanthia A Mitsiokapa; Kleo Th Papaparaskeva; Evanthia C Galanis; Panayotis N Soucacos
Journal:  World J Surg Oncol       Date:  2006-04-03       Impact factor: 2.754

8.  Aggressive juvenile fibromatosis of the paranasal sinuses: case report and brief review.

Authors:  Shaheen E Lakhan; Robert M Eager; Lindsey Harle
Journal:  J Hematol Oncol       Date:  2008-05-28       Impact factor: 17.388

9.  Susceptibility of fibromatosis cells in short-term culture to Ifosfamide: a possible experimental treatment in clinically aggressive cases.

Authors:  M W Verrill; H M Coley; I R Judson; C Fisher
Journal:  Sarcoma       Date:  1999

10.  Desmoid tumors in the pediatric population.

Authors:  Joshua N Honeyman; Michael P La Quaglia
Journal:  Cancers (Basel)       Date:  2012-03-09       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.